Myriad Genetics Inc (MYGN)vsNatera Inc (NTRA)
MYGN
Myriad Genetics Inc
$3.17
+4.97%
HEALTHCARE · Cap: $514.74M
NTRA
Natera Inc
$275.19
+1.79%
HEALTHCARE · Cap: $38.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 349% more annual revenue ($2.50B vs $557.00M). NTRA leads profitability with a -9.1% profit margin vs -41.3%. MYGN earns a higher WallStSmart Score of 44/100 (D).
MYGN
Hold44
out of 100
Grade: D
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.5%
Fair Value
$46.12
Current Price
$3.17
$42.95 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -118.5% — below average capital efficiency
Revenue declined 20.8%
0.0% earnings growth
Weak financial health signals
Trading at 22.1x book value
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MYGN
The strongest argument for MYGN centers on Price/Book. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : MYGN
The primary concerns for MYGN are EPS Growth, Market Cap, Return on Equity.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
MYGN profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.
MYGN carries more volatility with a beta of 1.64 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Bottom Line
MYGN scores higher overall (44/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Myriad Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Visit Website →Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?